HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced that members of the management team will participate at the
following upcoming investor conferences:
-
Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on
Tuesday, November 13, 2018, at 4:35 pm MT.
-
Piper Jaffray 30th Annual Healthcare Conference in New York City, NY
on Tuesday, November 27, 2018, at 3:50 pm ET.
-
Evercore ISI HealthCONx in Boston, MA on Wednesday, November 28, 2018,
at 10:15 am ET.
To access the live audio webcast of the presentations, please visit the
“Events & Presentations” section of the Arcus website at https://investors.arcusbio.com/investors/events-and-presentations.
A replay of the webcast will be available for 30 days following the live
event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist AB928, which is in a Phase 1/1b program to
evaluate AB928 in combination with other agents in multiple tumor types,
and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1
trial and is being tested in combination with Arcus’s other product
candidates. Arcus’s other programs include AB154, an anti-TIGIT
antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy
and in combination with AB122, and AB680, a small molecule inhibitor of
CD73, which is in IND-enabling studies. Arcus has extensive in-house
expertise in medicinal chemistry, immunology, biochemistry, pharmacology
and structural biology. For more information about Arcus Biosciences,
please visit www.arcusbio.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181101006030/en/
Arcus Biosciences
Jennifer Jarrett
(510) 694-6261
jjarrett@arcusbio.com
Or
Nicole
Arndt
(510) 284-4728
narndt@arcusbio.com
Source: Arcus Biosciences